Pentadecapeptide vs B7-33
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: BPC-157 Full Sequence, Stable Gastric Pentadecapeptide
Pentadecapeptide almost always means BPC-157, a synthetic 15-amino-acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. It is one of the most hyped 'healing' peptides online, marketed for tendon, gut, and muscle repair, but here is the catch: essentially all of the supporting evidence is from rats and mice. There is no FDA approval and no completed human clinical trial proving it does any of this.
Also: B7-33 relaxin, Single-chain relaxin-2 analog
B7-33 is a 27-amino-acid, single-chain peptide cut down from the B-chain of human relaxin-2, the hormone that loosens tissue during pregnancy. Relaxin itself has strong anti-scarring effects but is a complex two-chain molecule that is hard and expensive to make, so an Australian group (Hossain and colleagues, 2016) designed B7-33 as a simpler version. In rodent models it reduced heart and lung fibrosis about as well as full relaxin. It has never been tested in humans.
Key Comparison Insights
- Both peptides belong to the Healing category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Pentadecapeptide | B7-33 |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | BPC-157's proposed mechanism is still a hypothesis built mostly on animal work, not settled biology. The most consistent finding is that it appears to promote angiogenesis, the growth of new blood vessels, partly by upregulating the VEGFR2 (vascular endothelial growth factor receptor 2) pathway, which would help explain faster tissue repair. Researchers have also reported effects on the nitric oxide system and interactions with dopaminergic, serotonergic, and adrenergic signaling in rodents, which is sometimes invoked to explain its claimed gut-brain and mood effects. It does not have one clean, identified receptor the way a hormone does, and the molecular details remain unconfirmed in humans. | B7-33 activates RXFP1, the relaxin receptor, but in an unusual way. In cells that naturally carry RXFP1 (like fibroblasts), it preferentially switches on the pERK1/2 pathway rather than the cAMP pathway, which made it the first described functionally selective (biased) RXFP1 agonist. Its anti-fibrotic action runs through RXFP1 paired with the angiotensin II type 2 receptor, increasing MMP-2, an enzyme that breaks down collagen. In other words, it pushes scar tissue to be broken down rather than built up. Two practical caveats: it binds RXFP1 poorly in standard engineered cell lines, so its potency depends heavily on the cell type, and it is short-lived in serum (roughly 6 minutes in lab tests), which is why researchers have tried fatty-acid versions to stretch its half-life. |
| Common Dosing | Limited community data available See research protocols | No established human dose Once to twice daily in mouse studies |
| Administration | Subcutaneous injection | Intraperitoneal or subcutaneous injection (including osmotic minipumps) in rodents |
| Typical Duration | 4-12 weeks typical | 1-2 weeks in most rodent studies |
| Best Time to Take | Morning and evening (or near injury site timing) | No evidence-based timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The preclinical record is genuinely large and fairly consistent: across decades of rat and mouse studies, BPC-157 has accelerated healing of tendon, ligament, muscle, bone, and gut tissue, and protected against ulcers and various toxic insults, with one tendon study (Journal of Applied Physiology, 2011) showing it speeds tendon cell outgrowth, survival, and migration. That sounds impressive until you notice the gap between the lab bench and people. Recent reviews, including a 2025 MDPI literature and patent review and a 2025 narrative review in PMC, state plainly that there is no approved formulation, no validated human dose, and no completed Phase II trial. So while the animal data is real and reproducible, the human evidence is effectively zero, and claims about what it does in people are extrapolation, not proof. It is also banned by the World Anti-Doping Agency, which tells you it is treated as a performance drug, not a vetted medicine. | The founding paper (Hossain et al., Chemical Science, 2016) reported that B7-33 prevented or reversed organ fibrosis and dysfunction in three rodent models of heart or lung disease with potency similar to full relaxin-2, and, unlike native relaxin, it did not promote prostate tumor growth in mice. That last point matters because relaxin has been linked to tumor growth. Later mouse work extended the findings: Devarakonda et al. (Journal of the American Heart Association, 2020) gave 0.25 mg/kg twice daily by injection after a heart attack and found smaller infarcts, better heart function, and less fibrosis at 7 days. A 2023 follow-up from the original group confirmed that B7-33 cannot be shortened further without losing receptor binding. Important context: the full hormone (serelaxin) went all the way to a large phase 3 trial in acute heart failure (RELAX-AHF-2) and failed both primary endpoints, a reminder that strong animal anti-fibrotic data in this family have not translated easily to people. For B7-33 itself there are no human studies, no human pharmacokinetics, and no human safety data. |
Frequently Asked Questions: Pentadecapeptide vs B7-33
What is the difference between Pentadecapeptide and B7-33?
Pentadecapeptide is a healing peptide that pentadecapeptide almost always means bpc-157, a synthetic 15-amino-acid chain (gly-glu-pro-pro-pro-gly-lys-pro-ala-asp-asp-ala-gly-leu-val) derived from a protein found in human gastric juice. it is one of the most hyped 'healing' peptides online, marketed for tendon, gut, and muscle repair, but here is the catch: essentially all of the supporting evidence is from rats and mice. there is no fda approval and no completed human clinical trial proving it does any of this. B7-33 is a healing peptide that b7-33 is a 27-amino-acid, single-chain peptide cut down from the b-chain of human relaxin-2, the hormone that loosens tissue during pregnancy. relaxin itself has strong anti-scarring effects but is a complex two-chain molecule that is hard and expensive to make, so an australian group (hossain and colleagues, 2016) designed b7-33 as a simpler version. in rodent models it reduced heart and lung fibrosis about as well as full relaxin. it has never been tested in humans. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Pentadecapeptide or B7-33?
Neither is universally "better" - the choice depends on your specific goals. Pentadecapeptide is typically used for healing purposes, while B7-33 is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Pentadecapeptide and B7-33 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Pentadecapeptide and B7-33 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.